Надропарин в ургентной неврологии
Надропарин в ургентной неврологии
М.М.Танашян, М.А.Домашенко, М.А.Пирадов. Надропарин в ургентной неврологии. Consilium Medicum. Неврология (Прил.). 2008; 1: 32-36.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Stutzmann JM, Mary V, Wahl F et al. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev 2002; 8 (1): 1–30.
2. Сидоренко Б.А., Преображенский Д.В. Низкомолекулярные гепарины: возможности применения. Кардиология. 1995; 10: 86–90.
3. Kelly J, Rudd A, Lewis RR et al. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke 2004; 35: 2320–5.
4. Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc 1997; 72: 297–300.
5. Gould MK, Dembitzer AD, Sanders GD et al. Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999; 130: 789–99.
6. Hyers TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114 (suppl.): 561S–78S.
7. Sandercock PA, van den Belt AG, Lindley RI et al. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomized trials. J Neurol Neurosurg Psychiatry 1993; 56: 17–25.
8. Counsell C, Sandercock P. Low molecular weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review). Stroke 2002; 33 (7): 1925–6.
9. Turpie AG. Prophylaxis of venous thromboembolism in stroke patients. Semin Thromb Hemost 1997; 23: 155–7.
10. Verhaeghe R. On behalf of the SURYEX-study group. Eur J Surg 1994; 571: 35.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235–46.
12. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005; 3: 1187–94.
13. Kay R, Wong KS, Yu YL et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588–93.
14. Coull B, Williams L, Goldstein L et al. Anticoagulants and antiplatelet agents in acute ischemic stroke. Stroke 2002; 33 (7): 1934–42.
15. Chamorro A. Heparin in acute ischemic stroke: the case for a new clinical trial. Cerebrovasc Dis 1999; 9 (suppl. 3): 16–23.
16. Wakita M, Yasaka M, Minematsu K et al. Effects of anticoagulation on infarct size and clinical oitcome in acute cardioembolic stroke. Angiology 2002; 53 (5): 551–6.
2. Сидоренко Б.А., Преображенский Д.В. Низкомолекулярные гепарины: возможности применения. Кардиология. 1995; 10: 86–90.
3. Kelly J, Rudd A, Lewis RR et al. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke 2004; 35: 2320–5.
4. Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc 1997; 72: 297–300.
5. Gould MK, Dembitzer AD, Sanders GD et al. Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999; 130: 789–99.
6. Hyers TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114 (suppl.): 561S–78S.
7. Sandercock PA, van den Belt AG, Lindley RI et al. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomized trials. J Neurol Neurosurg Psychiatry 1993; 56: 17–25.
8. Counsell C, Sandercock P. Low molecular weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review). Stroke 2002; 33 (7): 1925–6.
9. Turpie AG. Prophylaxis of venous thromboembolism in stroke patients. Semin Thromb Hemost 1997; 23: 155–7.
10. Verhaeghe R. On behalf of the SURYEX-study group. Eur J Surg 1994; 571: 35.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235–46.
12. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005; 3: 1187–94.
13. Kay R, Wong KS, Yu YL et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588–93.
14. Coull B, Williams L, Goldstein L et al. Anticoagulants and antiplatelet agents in acute ischemic stroke. Stroke 2002; 33 (7): 1934–42.
15. Chamorro A. Heparin in acute ischemic stroke: the case for a new clinical trial. Cerebrovasc Dis 1999; 9 (suppl. 3): 16–23.
16. Wakita M, Yasaka M, Minematsu K et al. Effects of anticoagulation on infarct size and clinical oitcome in acute cardioembolic stroke. Angiology 2002; 53 (5): 551–6.
Авторы
М.М.Танашян, М.А.Домашенко, М.А.Пирадов
ГУ НЦН РАМН, Москва
ГУ НЦН РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.